Acorda preps FDA filing after Parkinson’s drug hits the primary endpoint in PhIII
Acorda’s $525 million gamble on a Phase III Parkinson’s drug has paid off. The biotech $ACOR announced early Thursday that the late-stage study of an inhaled rescue formulation of levodopa was a success, opening the door to a fast-approaching FDA application for marketing approval.
Acorda is reporting this morning that CVT-301 hit the primary endpoint in the study, demonstrating a significant improvement in motor skills over a placebo. CEO Ron Cohen scooped up the drug in an all-cash deal to acquire Civitas in late 2014.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.